US7642061B2 - Glut-1 as a receptor for HTLV envelopes and its uses - Google Patents

Glut-1 as a receptor for HTLV envelopes and its uses Download PDF

Info

Publication number
US7642061B2
US7642061B2 US10/555,289 US55528904A US7642061B2 US 7642061 B2 US7642061 B2 US 7642061B2 US 55528904 A US55528904 A US 55528904A US 7642061 B2 US7642061 B2 US 7642061B2
Authority
US
United States
Prior art keywords
glut1
htlv
seq
envelope protein
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US10/555,289
Other languages
English (en)
Other versions
US20080268424A1 (en
Inventor
Jean-Luc Georges Laurent Battini
Nicolas Gabriel Albert Manel
Felix Jinhyun Kim
Sandrina Kinet
Naomi Taylor
Marc Sitbon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Montpellier I
Universite de Montpellier
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Montpellier 2 Sciences et Techniques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Montpellier 2 Sciences et Techniques filed Critical Centre National de la Recherche Scientifique CNRS
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER II reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIM, FELIX JINHYUN, KINET, SANDRINA, MANEL, NICOLAS GABRIEL ALBERT, SITBON, MARC, TAYLOR, NAOMI, BATTINI, JEAN-LUC GEORGES LAURENT
Publication of US20080268424A1 publication Critical patent/US20080268424A1/en
Priority to US12/547,924 priority Critical patent/US8945583B2/en
Application granted granted Critical
Publication of US7642061B2 publication Critical patent/US7642061B2/en
Priority to US14/575,132 priority patent/US9777044B2/en
Priority to US15/698,661 priority patent/US20180002383A1/en
Assigned to Universite Montpellier reassignment Universite Montpellier MERGER (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITE MONTPELLIER 2
Assigned to UNIVERSITE DE MONTPELLIER reassignment UNIVERSITE DE MONTPELLIER CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED AT REEL: 047517 FRAME: 0408. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: UNIVERSITE MONTPELLIER 2
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae

Definitions

  • the invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1 represented by SEQ ID NO: 2, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linked to an overexpression of GLUT1 on cell surfaces, or the in vitro detection of GLUT1 on cell surfaces.
  • the invention also relates to pharmaceutical compositions containing GLUT1, or fragments or sequences derived thereof, and their uses such as in the frame of the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV.
  • HTLV human T-cell leukemia virus
  • HTLV envelope glycoproteins induce syncytium formation in vitro but their physiopathological effects are unclear. All vertebrate cell lines express functional HTLV envelope receptors, including cells resistant to HTLV envelope-mediated syncytium formation. We found that expression of the HTLV receptor-binding domain decreased lactate production due to diminished glucose consumption whereas binding-defective envelope mutants did not alter glucose metabolism. Glucose starvation increased HTLV receptor expression, reminiscent of nutrient sensing responses. Accordingly, overexpression of GLUT-1, the ubiquitous vertebrate glucose transporter, specifically increased HTLV envelope binding and GLUT-1 colocalized with HTLV envelopes.
  • HTLV envelope binding was highest in human erythrocytes, where GLUT-1 is abundantly expressed and is the sole glucose transporter isoform.
  • the invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1 represented by SEQ ID NO: 2, or of fragments or sequences derived thereof, said fragments or derived sequences being able to bind to the envelope proteins of the primate T-cell leukemia viruses (PTLV), or of cells expressing GLUT1, for:
  • PTLV primate T-cell leukemia viruses
  • said compounds being selected for their ability to bind specifically to said GLUT1,
  • PTLV HTLV-1, HTLV-2, STLV-1, STLV-2, STLV-3, or their variants, or linked to the presence of PTLV SU-related sequences in such individuals or animals,
  • screened compounds mentioned above can be selected for their ability to bind specifically to said GLUT1, or fragments of GLUT1, according to the following method using a EGFP-tagged GLUT1-binding component derived from PTLV RBD (receptor binding domain) as an example of such compound able to bind to GLUT1.
  • a EGFP-tagged GLUT1-binding component derived from PTLV RBD receptor binding domain
  • a EGFP-tagged Glut1-binding component derived from PTLV RBD is applied onto live or fixed suspension or attached cells. After washes with appropriate buffer, cells are incubated for 30 min at RT, washed and analyzed or quantified as attached on an appropriate support on a fluorescent microscope or as individual cell suspension on a fluorescent analysis ell sorter (FACS).
  • a non-fluorescent GLUT1-binding component derived from PTLV RBD is applied as described above and revealed with a secondary fluorochrome-tagged reagent such as a fluorochrome-tagged secondary antibody directed against the PTLV RBD or against a non fluorochrome tag attached to the said PTLV RBD component.
  • the invention relates more particularly to the use as defined above, of fragments of GLUT1 chosen among the followings:
  • SEQ ID NO: 25 NAPQKVIEEFY SEQ ID NO: 26: NQTWVHRYGESILPTTLTTLWS SEQ ID NO: 27: KSFEMLILGR SEQ ID NO: 28: DSIMGNKDL SEQ ID NO: 29: YSTSIFEKAGVQQP SEQ ID NO: 30: EQLPWMSYLS SEQ ID NO: 31: QYVEQLC SEQ ID NO: 32: IVGMCFQYVEQLC
  • the invention also concerns the use of compounds selected for their ability to bind specifically to GLUT1 as defined above, for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, such as pathologies corresponding to adult T cell leukemia (ATL), HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), as well as other HTLV-associated syndromes such as large granular lymphocyte (LGL) leukaemia (Loughran, T. P., K. G. Hadlock, R. Perzova, T. C. Gentile, Q. Yang, S. K. Foung, and B. J. Poiesz. 1998.
  • ATL adult T cell leukemia
  • HAM/TSP HTLV-I-associated myelopathy/tropical spastic paraparesis
  • LGL large granular lymphocyte
  • T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis. J Infect Dis. 2002 Nov. 1; 186(9):1231-41), and potentially other idiopathic diseases in which PTLV or PTLV sequences may be involved.
  • the invention relates more particularly to the use for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, of compounds chosen among the followings:
  • cytochalasin B forskolin, dipyridamole, isobutylmethylxanthine (20: Hellwig B, Joost HG. Differentiation of erythrocyte-(GLUT1), liver-(GLUT2), and adipocyte-type (GLUT4) glucose transporters by binding of the inhibitory ligands cytochalasin B, forskolin, dipyridamole, and isobutylmethylxanthine. Mol. Pharmacol. 1991 September; 40(3):383-9),
  • Genistein is a natural inhibitor of hexose and dehydroascorbic acid transport through the glucose transporter, GLUT1. J Biol. Chem. 1996 Apr. 12; 271(15):8719-24),
  • dehydroascorbic acid (Rumsey S C, Kwon O, Xu G W, Burant C F, Simpson I, Levine M. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J Biol. Chem. 1997 Jul. 25; 272(30):18982-9),
  • peroxisome proliferator-activated receptors such as thiazolidinedione (troglitazone, pioglitazone, rosiglitazone)
  • TZDs modify astrocyte metabolism and mitochondrial function, which could be beneficial in neurological conditions where glucose availability is reduced” from Dello Russo C, Gavrilyuk V, Weinberg G, Almeida A, Bolanos J P, Palmer J, Pelligrino D, Galea E, Feinstein D L.
  • Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol. Chem. 2003 Feb. 21; 278(8):5828-36).
  • the invention also relates to the use of compounds selected for their ability to bind specifically to GLUT1 as defined above, for the preparation of drugs for the prevention or the treatment of pathologies linked to an overexpression of GLUT1 on cell surfaces, such as:
  • the invention relates more particularly to the use for the preparation of drugs for the prevention or the treatment of pathologies linked to an overexpression of GLUT1 on cell surfaces, of compounds chosen among the followings:
  • the invention relates more particularly to the use of polypeptides corresponding to the envelope proteins of PTLV, or fragments or sequences derived thereof, said polypeptides being selected for their ability to bind specifically to the ubiquitous vertebrate glucose transporter GLUT1 represented by SEQ ID NO: 2, or of nucleotide sequences encoding said polypeptides, for the preparation of drugs for the prevention or the treatment of pathologies linked to an overexpression of GLUT1 on cell surfaces, and the in vitro diagnosis of said pathologies.
  • the invention concerns more particularly the use as defined above, of polypeptides able to bind to at least one of the above mentioned fragments of GLUT1 corresponding to SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, and SEQ ID NO: 32.
  • the invention concerns more particularly the use as defined above, of polypeptides able to bind to at least the fragment of GLUT1 corresponding to SEQ ID NO: 32.
  • the invention concerns more particularly the use as defined above, of GLUT1 binding polypeptides mentioned above chosen among the followings:
  • the invention concerns more particularly the use mentioned above of GLUT1 binding polypeptides as defined above, characterized in that the treated or detected pathologies are the followings:
  • the invention relates more particularly to the use of compounds selected for their ability to bind specifically to GLUT1 as mentioned above, and more particularly GLUT1 binding polypeptides as defined above, for the in vitro detection of GLUT1 on cell surfaces in the frame of processes for the in vitro diagnosis of pathologies linked to an overexpression of GLUT1 on cell surfaces, such as pathologies defined above, said processes comprising the following steps:
  • the invention concerns more particularly the use of compounds as defined above for the in vitro diagnosis of cancers, characterized in that the compounds used are chosen among the compounds defined above selected for their ability to bind specifically to GLUT1.
  • the invention relates more particularly to the use as defined above, of GLUT1 binding polypeptides, or of nucleotide sequences encoding said polypeptides, for the preparation of drug vectors containing at their surface said polypeptides, said vectors being useful for targeting GLUT1 overexpressing cells for the prevention or the treatment of pathologies linked to an overexpression of GLUT1 on cell surfaces, said vectors containing molecules active against said pathologies, or containing genes in the frame of gene therapy of these pathologies.
  • the invention relates more particularly to the use as defined above, of GLUT1 binding polypeptides, or of nucleotide sequences encoding said polypeptides, for the preparation of drug vectors containing at their surface GLUT1 binding polypeptides, said vectors being useful for targeting GLUT1 overexpressing tumor cells, or cells involved in the inflammatory mechanism, or activated cells of the immune system, or cells of the central nervous system, for the prevention or the treatment of related pathologies as defined above.
  • the invention concerns more particularly the use of GLUT1 binding polypeptides, or of nucleotide sequences encoding said polypeptides, for the preparation of drug vectors as defined above, wherein the molecules active against the pathologies are antitumor molecules, or molecules against inflammatory conditions, immune or auto-immune diseases, or disorders of the central nervous system.
  • the invention also relates to the use of nucleotide sequences encoding polypeptides compounds selected for their ability to bind specifically to GLUT1 as defined above, such as nucleotide sequences encoding the polypeptides defined above, or fragments thereof, for the preparation, by substitution of one or several nucleotides of said nucleotide sequences, of mutant nucleotide sequences encoding corresponding mutant polypeptides unable to bind to GLUT1.
  • the invention also concerns the use of mutant polypeptides unable to bind to GLUT 1 as defined above:
  • the invention relates more particularly to the use as defined above, of mutant polypeptides corresponding to the polypeptides defined above, wherein:
  • the invention also relates to the use of mutant nucleotide sequences encoding corresponding mutant polypeptides unable to bind to GLUT1 as defined above, for the preparation of transgenic mammal cells expressing said mutant polypeptides, said cells having a negative transdominant effect with regard to PTLV, thus preventing infection and dissemination of this latter in the organism.
  • the invention also concerns pharmaceutical compositions containing GLUT1 represented by SEQ ID NO: 2, or fragments or sequences derived thereof, said fragments or derived sequences being able to bind to the envelope proteins of the primate T-cell leukemia viruses (PTLV), in association with a pharmaceutically acceptable carrier.
  • GLUT1 represented by SEQ ID NO: 2, or fragments or sequences derived thereof, said fragments or derived sequences being able to bind to the envelope proteins of the primate T-cell leukemia viruses (PTLV), in association with a pharmaceutically acceptable carrier.
  • PTLV primate T-cell leukemia viruses
  • the invention relates more particularly to pharmaceutical compositions containing mutant polypeptides corresponding to the polypeptides defined above, wherein:
  • the invention also concerns transgenic mammal cells expressing mutant polypeptides unable to bind to GLUT1 as defined above, said cells having a negative transdominant effect with regard to PTLV, thus preventing infection and dissemination of this latter in the organism.
  • the invention relates more particularly to pharmaceutical compositions containing transgenic mammal cells as defined above, in association with a pharmaceutically acceptable carrier.
  • the invention also concerns therapeutic vectors useful for targeting GLUT1 overexpressing cells in pathologies linked to an overexpression of GLUT1 on cell surfaces, such as defined above, said vectors containing at their surface GLUT1 binding polypeptides chosen among those defined above, and containing molecules active against said pathologies, as defined above, or containing genes in the frame of gene therapy.
  • the invention relates more particularly to pharmaceutical compositions containing therapeutic vectors as described above, in association with a pharmaceutically acceptable carrier.
  • the invention also relates to a method for the screening of compounds useful for:
  • said method comprising:
  • the invention relates more particularly to a method for the screening of compounds useful for the prevention or the treatment of pathologies linked to an overexpression of GLUT1 on cell surfaces, and the in vitro diagnosis of said pathologies, comprising the steps described above:
  • the invention also concerns a method for the in vitro diagnosis pathologies linked to an overexpression of GLUT1 on cell surfaces, characterized in that it comprises:
  • the invention relates more particularly to a method as defined above for the in vitro diagnosis of pathologies mentioned above.
  • the invention also concerns a kit for the in vitro diagnosis of pathologies linked to a n overexpression of GLUT1 on cell surfaces as described above, comprising compounds, and more particularly polypeptides, selected for their ability to bind specifically to GLUT1 as defined above, said compounds or polypeptides being optionally labeled, and, if necessary reagents for the detection of the binding of said compounds or polypeptides to GLUT1 initially present on cell surfaces in the biological sample.
  • HTLV human T-cell leukemia virus
  • ATL adult T cell leukemia
  • TSP/HAM tropical spastic paraparesis/HTLV-associated myelopathy
  • HTLV Env-mediated syncytia formation Numerous cell surface components have been shown to play a role in HTLV Env-mediated syncytia formation [Niyogi, 2001; Daenke, 1999; Hildreth, 1997]. Nevertheless, HTLV Env-dependent cell membrane fusion and syncytia formation appear to be distinct from receptor binding per se [Denesvre, 1996; Daenke, 2000; Kim, 2000; Kim, 2003]. The search for HTLV Env receptor has been hindered in part by its ubiquitous presence [Sutton, 1996; Trejo, 2000; Jassal, 2001; Kim, 2003].
  • H1 RBD HTLV-1 RBD
  • D106A and Y114A RBD mutants were expressed and secreted as efficiently as the wild-type H1 RBD ( FIG. 2 a ), they exhibited significantly reduced (D106A) or non detectable (Y114A) binding to the HTLV receptor as detected by FACS analysis ( FIG. 2 b ).
  • lactate accumulation was not reduced in cells expressing the non-binding Y114A RBD mutant and was minimally reduced in cells harboring the D106 RBD ( FIG. 2 c ). Similar results were obtained with H2 RBD harboring the same allelic mutations. These data favor a direct association between lactate-related metabolic alterations and HTLV Env receptor binding.
  • Extracellular lactate accumulates in cell cultures following its transport across cellular membranes by the MCT1 monocarboxylate transporter [Garcia, 1994]. Because HTLV and MLV share a common organization of the extracellular envelope [Kim, 2000] and the receptors for MLV Env are multispanning metabolite transporters [Overbaugh, 2001], we assessed whether the HTLV RBD bound to MCT1. Moreover, similar to our previous data concerning expression of the HTLV receptor on T cells [Manel, 2003], expression of MCT1 chaperone CD 147 [Kirk, 2000] increases during T cell activation [Kasinrerk, 1992]. However, separate and combined overexpression of MCT1 and CD147 did not result in increased H1 RBD binding, arguing against a role for these molecules as receptors for HTLV Env.
  • GLUT-1 appears to be the only one encompassing all the known properties of the HTLV receptor. Indeed, GLUT-1 expression is increased upon glucose deprivation and is transports glucose in all vertebrate cells [Mueckler, 1985], while fructose is transported by GLUT-5. Furthermore, GLUT-1 is not expressed on resting primary T cells and its expression is induced upon T cell activation [Rathmell, 2000; Chakrabarti, 1994] with kinetics that are strikingly similar to what we have reported for the HTLV receptor [Manel, 2003].
  • GLUT-1 could be readily detected upon immunoprecipitation with anti-rabbit-Fc-beads when it was co-expressed with H1 RBD , but could not be detected when expressed alone or with the H1 RBD Y114A mutant.
  • a GFP-tagged HTLV-2 RBD colocalized with GLUT-1 but not with PiT2 as assessed by fluorescence microscopy. Therefore, the GLUT-1 glucose transporter is an essential component of the HTLV envelope receptor.
  • cytochalasin B Interaction of GLUT-1 with its ligand cytochalasin B inhibits glucose transport [Kasahara, 1977]. Since we showed that binding of HTLV envelopes to GLUT-1 inhibits glucose consumption and uptake, we tested whether cytochalasin B would abrogate HTLV RBD binding. Indeed, cytochalasin B treatment of Jurkat T cells dramatically inhibited binding of H1 RBD , whereas binding of A RBD was not affected ( FIG. 5 a ). Thus, GLUT-1 directed glucose transport as well as binding of HTLV envelopes to GLUT-1 are similarly inhibited by the cytochalasin B ligand. Altogether, these data demonstrate that GLUT-1 is a receptor for HTLV envelopes.
  • Viral receptor permits entry and thus infection.
  • No cellular system currently exists that lacks GLUT-1 expression.
  • HTLV infection is specifically inhibited at the level of envelope-receptor interaction.
  • over-expression of HTLV-2 RBD interferes with infecting incoming HTLV particles and specifically decreases HTLV titers by at least 2 logs, while no effect is detected on control A-MLV titers.
  • GLUT-1 is an entry receptor for HTLV
  • GLUT-3 or Pit2 in addition to the interfering H2 RBD .
  • GLUT-1 is an entry receptor for HTLV.
  • HTLV-1 and -2 envelopes interact with GLUT-1 through their receptor binding domains. This interaction strongly inhibits glucose consumption and glucose uptake, leading to decreased lactate production and a block in extracellular milieu acidification. Mutations that specifically altered receptor binding of both HTLV-1 and 2 envelopes released the block in glucose consumption, indicative of a direct correlation between receptor binding determinants in the HTLV envelopes and glucose transport. Glucose starvation was rapidly followed by increased binding of HTLV envelopes, highlighting a nutrient-sensing negative feedback loop between glucose availability and cell surface HTLV receptor expression.
  • GLUT-1 As the receptor, including increased binding of HTLV RBD upon overexpression of GLUT-1 but not GLUT-3, immunoprecipitation of GLUT-1 by H1 RBD but not the receptor-binding mutant H1 RBD Y114A, uppermost binding of HTLV RBD on human erythrocytes, where GLUT-1 is the major glucose transporter isoform, and no binding of HTLV RBD on human primary hepatocytes and murine erythrocytes, where GLUT-1 is minimally expressed. Finally, GLUT-1 could specifically alleviate interference to infection induced by HTLV RBD. GLUT-1 fits all other known properties of the HTLV receptor.
  • GLUT-1 is not expressed on resting T lymphocytes [Chakrabarti, 1994; Korgun, 2002] and is induced upon immunological [Frauwirth, 2002; Yu, 2003] or pharmacological [Chakrabarti, 1994] activation.
  • GLUT-1 orthologues are highly conserved among vertebrates, but are highly divergent between vertebrates and insects [Escher, 1999].
  • GLUT-1 is thus a new member of the multimembrane spanning metabolite transporters that serve as receptors for retroviral envelopes.
  • all envelopes that recognize these receptors have been encoded by retroviruses that have a so-called simple genetic organization, such as MLV, feline leukemia viruses, porcine endogenous retrovirus and the gibbon ape leukemia virus [Overbaugh, 2001], whereas HTLV belongs to the so-called complex retroviruses which code for several additional regulatory proteins.
  • MLV simple genetic organization
  • HTLV belongs to the so-called complex retroviruses which code for several additional regulatory proteins.
  • the envelopes of HTLV and MLV share a similar modular organization with some highly conserved amino acid motifs in their respective receptor binding domains [Kim, 2000].
  • HTLV envelope receptor is associated to the cytoskeleton.
  • a cytoplasmic-binding partner of GLUT-1, GLUT1CBP which encodes a PDZ domain, has been reported to link GLUT-1 to the cytoskeleton [Bunn, 1999]. It will therefore be interesting to evaluate the respective roles of the HTLV envelope, its cytoskeleton-associated cellular partners, such as GLUT-1, GLUT1CBP and their immediate interacting cell components.
  • HTLV receptor is induced upon glucose starvation
  • transmission of HTLV may be more efficient in cells that are locally starved for glucose, such as lymphocytes in lymph nodes [Yu, 2003].
  • lymphocytes in lymph nodes [Yu, 2003].
  • the ability of circulating erythrocytes to dock HTLV might provide a means to distribute HTLV to such tissues.
  • GLUT-1 as a receptor for HTLV envelopes provides additional clues as to the ubiquitous in vitro expression of the receptor on cell lines and the paradoxical restriction of HTLV tropism to T lymphocytes in vivo. Rapid and dramatic metabolic alterations associated with the blockade of glucose consumption are likely to take place upon expression of the HTLV envelope in vivo, early after infection. Therefore, we propose that in vivo, HTLV infection initially spreads with a large tropism, however early after infection the vast majority of cells that are highly dependent on GLUT-1 activity are rapidly eliminated. In contrast, resting T lymphocytes that have an extremely low metabolic rate and as such are much less dependent on glucose uptake, can tolerate this effect and are therefore maintained in vivo.
  • DMEM Dulbecco's modified Eagle medium
  • FBS fetal bovine serum
  • cells were grown in either glucose-free DMEM (Life Technologies) or glucose-free RPMI—(Dutscher) with 10% dialyzed FBS (Life Technologies) and glucose (1 g/l) was supplemented when indicated.
  • Full length envelope expression vectors for amphotropic MLV (pCSI.A), or devoid of its R peptide (pCSI.A ⁇ R), and H 183 FEnv that contains the N-terminal 183 amino acids of the HTLV-1 receptor-binding domain in the F-MLV envelope background, as well as truncated envelope expression vectors, derived from pCSI and encoding either of the first 215 residues of HTLV-1 SU (H1 RBD ), the first 178 residues of HTLV2-SU (H2 RBD ) or the first 397 residues of the amphotropic murine leukemia virus (MLV) SU (A RBD ), fused to a C-terminal rabbit IgG Fc tag (rFc) or to EGFP (H2 RBD -GFP).
  • H1 RBD the first 215 residues of HTLV-1 SU
  • H2 RBD the first 178 residues of HTLV2-SU
  • a RBD amphotropic murine leukemia
  • HTLV-1 and -2 RBD constructs All point mutations introduced in HTLV-1 and -2 RBD constructs were generated using the quickchange site-directed mutagenesis method and mutations were verified by sequencing.
  • Human Glut-1 and Glut-3 cDNA were amplified by PCR from the pLib HeLa cDNA library (Clontech), and inserted into pCHIX, a modified version of the pCSI vector that contains a cassette comprising a factor Xa cleavage site, two copies of the hemagglutinin (HA) tag, and a histidine tag.
  • the resulting construct (pCHDC.hGLUT1) encodes a GLUT-1 protein with a HA-His tag at the C-terminal end.
  • GLUT-1 and GLUT-3 were also inserted in a modified pCSI vector containing a DsRed2 C-terminal tag.
  • human CD147 was amplified from 293T total RNA by RT-PCR and inserted into the pCHIX backbone in frame with the HA-His tag (pCHIX.hCD147).
  • 293T cells were transfected with the various envelope expression vectors using a modified version of the calcium phosphate method. After an overnight transfection, cells were washed in phosphate-buffered saline (PBS) and fresh medium was added. Media were harvested at the indicated time points, filtered through a 0.45- ⁇ m pore-size filter, and lactate and glucose were measured with enzymatic diagnostic kits (Sigma).
  • PBS phosphate-buffered saline
  • Uptake was initiated by adding labeled hexoses to a final concentration of 0, 1 mM (2 ⁇ Ci/ml for 2-2-deoxy-D[1- 3 H]glucose and 0, 2 ⁇ Ci/ml for D[U- 14 C]fructose and 3-O-[ 14 C]methyl-D-glucose) and cells were incubated for 5′ additional minutes. Cells were then resuspended in 500 ⁇ l cold serum-free glucose-free DMEM, wash one time in serum-free glucose-free DMEM, and solubilized in 400 ⁇ l of 0, 1% SDS. 3 ⁇ l was used for Bradford normalization, while the rest was used for detection of either 3 H or 14 C by liquid scintillation in a Beckman counter.
  • Binding assays were carried out as previously described [Manel, 2003]. Briefly, 5 ⁇ 10 5 cells (293T, HeLa, Jurkat or freshly isolated human erythrocytes) were incubated with 500 ⁇ l of H1 RBD , H2 RBD or A RBD supernatants for 30 min at 37° C., washed with PBA (1% BSA, 0.1% sodium azide in PBS), and incubated with a sheep anti-rabbit IgG antibody conjugated to fluorescein isothiocyanate (Sigma). When indicated, cytochalasin B (20 ⁇ M; Sigma) was added to cells for 1 hour prior to binding analyses. Binding was analyzed on a FACSCalibur (Becton Dickinson) and data analysis was performed using CellQuest (Becton Dickinson) and WinMDI (Scripps) softwares.
  • Infections 293T cells were transfected in 6-wells plate, and one day after transfection, medium was replaced by high glucose DMEM supplemented with fructose (5 g/l) and non-essential amino acids. The next day, infection was initiated by adding supernatants containing MLV particles pseuodtyped with either HTLV-2 or A-MLV envelopes. The following day, fresh medium was added, and 24 hours later cells were fixed and stained for alkaline phosphatase activity and dark focus of infection were counted. Viral particles were obtained by transfecting 293T cells with pLAPSN, pGagPoule and either pCSIX.H2 or pCSI.A, and harvesting the 0.45 ⁇ m-filtered supernatants 24 hours latter.
  • FIG. 1 Expression of the HTLV receptor-binding domain alters cellular metabolism.
  • a Medium acidification and syncytia formation in 293T cells one day post-transfection with control DNA or Env expression vectors, including syncytial wild-type HTLV-1 Env and HTLV-2 Env, a non-syncytial chimeric H 183 FEnv, and syncytial A-MLV ⁇ R Env.
  • b Extracellular lactate and glucose in the culture medium of 293T cells were measured two days following transfection with an irrelevant DNA (control), F-MLV Env, H 183 FEnv, HTLV-1 RBD (H1 RBD ) or amphotropic MLV RBD (A RBD ) expression vectors.
  • Lactate and glucose concentrations were normalized to cellular protein content.
  • c 2-deoxyglucose and fructose uptake following transfection of 293T with an irrelevant DNA (control), H1 RBD , H2 RBD or A RBD expression vectors. Control cells were also incubated with glucose transporter inhibitors cytochalasin and phloretin. Data are the means of triplicate measures and are representative of two to three independent experiments.
  • d Expression of the HTLV and amphotropic-MLV receptors on 293T (1) and Jurkat T (2) cells cultured overnight in the presence or absence of glucose was monitored by binding of H1 RBD and A RBD , respectively.
  • FIG. 2 HTLV receptor properties correlates with GLUT1 properties.
  • a Expression of the HTLV and amphotropic-MLV receptors at the surface of human and murine erythrocytes, as well as human primary hepatocytes.
  • b H1 RBD and A RBD binding to Jurkat cells in the absence or presence of the Glut-1 inhibitor cytochalasin B.
  • FIG. 3 HTLV receptor-binding correlates with altered lactate metabolism
  • a Expression of H1 RBD and the derived mutants D106A and Y114A was monitored by Western blot analysis of the supernatants of 293T cells following transfection with the various expression plasmids.
  • b Binding of H1 RBD and the D106A and Y114A mutants to the HTLV receptor on HeLa cells.
  • c Extracellular lactate in the medium of 293T cells one day post transfection with an irrelevant DNA (control), H1 RBD or the H1 RBD D106A and Y114A mutants. Data are representative of three independent experiments.
  • FIG. 4 GLUT-1 is a receptor for HTLV envelopes.
  • a Binding of H1 RBD , H2 RBD , H2 RBD D102A mutant, and A RBD to control 293T cells or 293T cells overexpressing either GLUT-1 or PiT2.
  • b Binding of H2 RBD -EGFP to cells overexpressing GLUT-1-HA or GLUT-3-HA, and corresponding immunoblots using an anti-HA antibody.
  • GLUT-1-HA Immunprecipitation of GLUT-1-HA from 293T cells transfected with either an irrelevant construct, GLUT-1 alone, H1RBD alone, H1RBD Y114A alone, GLUT-1 with H1 RBD or GLUT-1 with H1 RBD Y114A expression vectors. Immunoprecipitation was performed using anti-rabbit-Fc beads and probed with an anti-HA antibody. Total cell extracts were blotted using an anti-rabbit Fc or an anti-HA antibody.
  • FIG. 5 GLUT-1 is an entry receptor for HTLV. Infections titer of MLV particles pseudotypes with HTLV-2 or A-MLV envelopes on 293T cells following transfection of an irrelevant or interfering H2 RBD expression vectors alone or in addition to GLUT-1, GLUT-3 or Pit2 expression vectors.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
US10/555,289 2003-05-02 2004-04-30 Glut-1 as a receptor for HTLV envelopes and its uses Active 2026-08-05 US7642061B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/547,924 US8945583B2 (en) 2003-05-02 2009-08-26 GLUT-1 as a receptor for HTLV envelopes and its uses
US14/575,132 US9777044B2 (en) 2003-05-02 2014-12-18 GLUT-1 as a receptor for HTLV envelopes and its uses
US15/698,661 US20180002383A1 (en) 2003-05-02 2017-09-08 Glut-1 as a receptor for htlv envelopes and its uses

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03291067 2003-05-02
EP03291067.1 2003-05-02
PCT/EP2004/004624 WO2004096841A1 (fr) 2003-05-02 2004-04-30 Glut-1 comme recepteur pour les enveloppes htlv et ses utilisations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/004624 A-371-Of-International WO2004096841A1 (fr) 2003-05-02 2004-04-30 Glut-1 comme recepteur pour les enveloppes htlv et ses utilisations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/547,924 Division US8945583B2 (en) 2003-05-02 2009-08-26 GLUT-1 as a receptor for HTLV envelopes and its uses

Publications (2)

Publication Number Publication Date
US20080268424A1 US20080268424A1 (en) 2008-10-30
US7642061B2 true US7642061B2 (en) 2010-01-05

Family

ID=33396025

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/555,289 Active 2026-08-05 US7642061B2 (en) 2003-05-02 2004-04-30 Glut-1 as a receptor for HTLV envelopes and its uses
US12/547,924 Active 2026-06-28 US8945583B2 (en) 2003-05-02 2009-08-26 GLUT-1 as a receptor for HTLV envelopes and its uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/547,924 Active 2026-06-28 US8945583B2 (en) 2003-05-02 2009-08-26 GLUT-1 as a receptor for HTLV envelopes and its uses

Country Status (6)

Country Link
US (2) US7642061B2 (fr)
EP (3) EP2610265B1 (fr)
JP (1) JP5612239B2 (fr)
DK (1) DK1648926T3 (fr)
ES (1) ES2740827T3 (fr)
WO (1) WO2004096841A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150133363A1 (en) * 2003-05-02 2015-05-14 Centre National De La Recherche Scientifique (Cnrs) Glut-1 as a receptor for htlv envelopes and its uses
US10231831B2 (en) 2009-12-08 2019-03-19 Cardiovalve Ltd. Folding ring implant for heart valve

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5612239B2 (ja) * 2003-05-02 2014-10-22 サントル ナシオナル ドゥ ラ ルシェルシェ シアンティフィクＣｅｎｔｒｅ Ｎａｔｉｏｎａｌ Ｄｅ Ｌａｒｅｃｈｅｒｃｈｅ Ｓｃｉｅｎｔｉｆｉｑｕｅ Ｈｔｌｖエンベロープのレセプターとしてのｇｌｕｔ１及びその使用
WO2007041268A2 (fr) * 2005-09-30 2007-04-12 Xenoport, Inc. Diagnostic et traitement a ciblage par le transporteur
US9791435B2 (en) * 2009-01-09 2017-10-17 Centre National De La Recherche Scientifique Receptor binding ligands, their use in the detection of cells with biological interest
WO2012035369A1 (fr) * 2010-09-17 2012-03-22 Centre National De La Recherche Scientifique Procédé pour le diagnostic et/ou le pronostic d'états inflammatoires
IL282053B2 (en) * 2015-03-10 2023-03-01 Univ Columbia Constructions of glut1-linked recombinant aav vectors, preparations and kits containing them and their use
EP3861350A1 (fr) 2018-10-05 2021-08-11 Metafora Biosystems Utilisation de ligands dérivés du domaine de liaison au récepteur de rétrovirus endogène porcin de type b permettant le diagnostic de maladies associées à smvt
CN113527429B (zh) * 2020-04-15 2024-04-16 辽宁中健医药科技有限公司 人肝癌细胞特异结合多肽及其用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005783A1 (fr) 1987-01-28 1988-08-11 Ortho Pharmaceutical Corporation Peptides immunodepresseurs et leurs procedes d'utilisation
WO1992013946A1 (fr) 1991-02-08 1992-08-20 Genelabs Technologies, Inc. Antigenes de peptides de htlv-i et htlv-ii et procedes
WO1996021727A1 (fr) 1995-01-13 1996-07-18 Virogenetics Corporation Compositions immunogenes contenant des virus pox attenues exprimant des antigenes de htlv
WO1996041193A1 (fr) 1995-06-07 1996-12-19 Mount Sinai School Of Medicine Of The City University Of New York Procede immunocytochimique de tres grande sensibilite pour le diagnostic des epanchements tumoraux
WO1997015668A2 (fr) 1995-10-23 1997-05-01 Board Of Regents, The University Of Texas System Procedes et compositions comprenant glut-2 et des chimeres de glut-2
WO1998003197A1 (fr) 1996-07-22 1998-01-29 The Rockefeller University Vaccin a base de glycoproteine d'enveloppe destine a proteger contre l'infection a htlv-i et htlv-ii
US5897991A (en) * 1995-06-07 1999-04-27 The Mount Sinai Medical Center Highly sensitive immunocytochemical method for diagnosis of malignant effusions
WO1999045920A2 (fr) 1998-03-13 1999-09-16 Johns Hopkins University School Of Medicine Traitement de la retinopathie diabetique ou des inflammations oculaires au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine
WO1999059559A1 (fr) 1998-05-15 1999-11-25 Joslin Diabetes Center Regulation independante de transport de glucose basal et stimule par insuline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5612239B2 (ja) * 2003-05-02 2014-10-22 サントル ナシオナル ドゥ ラ ルシェルシェ シアンティフィクＣｅｎｔｒｅ Ｎａｔｉｏｎａｌ Ｄｅ Ｌａｒｅｃｈｅｒｃｈｅ Ｓｃｉｅｎｔｉｆｉｑｕｅ Ｈｔｌｖエンベロープのレセプターとしてのｇｌｕｔ１及びその使用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005783A1 (fr) 1987-01-28 1988-08-11 Ortho Pharmaceutical Corporation Peptides immunodepresseurs et leurs procedes d'utilisation
WO1992013946A1 (fr) 1991-02-08 1992-08-20 Genelabs Technologies, Inc. Antigenes de peptides de htlv-i et htlv-ii et procedes
WO1996021727A1 (fr) 1995-01-13 1996-07-18 Virogenetics Corporation Compositions immunogenes contenant des virus pox attenues exprimant des antigenes de htlv
WO1996041193A1 (fr) 1995-06-07 1996-12-19 Mount Sinai School Of Medicine Of The City University Of New York Procede immunocytochimique de tres grande sensibilite pour le diagnostic des epanchements tumoraux
US5897991A (en) * 1995-06-07 1999-04-27 The Mount Sinai Medical Center Highly sensitive immunocytochemical method for diagnosis of malignant effusions
WO1997015668A2 (fr) 1995-10-23 1997-05-01 Board Of Regents, The University Of Texas System Procedes et compositions comprenant glut-2 et des chimeres de glut-2
WO1998003197A1 (fr) 1996-07-22 1998-01-29 The Rockefeller University Vaccin a base de glycoproteine d'enveloppe destine a proteger contre l'infection a htlv-i et htlv-ii
WO1999045920A2 (fr) 1998-03-13 1999-09-16 Johns Hopkins University School Of Medicine Traitement de la retinopathie diabetique ou des inflammations oculaires au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine
WO1999059559A1 (fr) 1998-05-15 1999-11-25 Joslin Diabetes Center Regulation independante de transport de glucose basal et stimule par insuline

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Brown (Journal of Inherited Metabolic Diseases 23:237-246, 2000). *
Harris D S et al: "Polarized Distribution of Glucose Transporter Isoforms in CACO-2 Cells", Proceedings of the National Academy of Sciences of the United States, vol. 89, No. 16, 1992, pp. 7556-7560, XP002254293, 1992 ISSN: 0027-8424, p. 7557, col. 1, line 4-line 11 p. 7557, col. 2, paragraph 2; figures 1, 3A, p. 7559, col. 2, last paragraph.
Lairmore M D et al: "Characterization of A B-Cell Immunodominant Epitope of Human T-Lymphotropic Virus Type 1 (HTLV-I) Envelope GP46" Cancer Letters, New York, NY, US, vol. 66, Sep. 14, 1992, pp. 11-20, XP000940582, ISSN: 0304-3835 abstract.
Manel Nicolas et al: "GLUT-1 is the receptor of retrovirus HTLV!" Medecine Sciences: M/S. Mar 2004, vol. 20, No. 3, Mar. 2004, pp. 277-279, XP002293056, ISSN: 0767-0974, the whole document.
Manel Nicolas et al: "The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV." Cell, vol. 115, No. 4, Nov. 14, 2003, pp. 449-459, XP002293058, ISSN: 0092-8674, the whole document.
Mendez Luis E et al: "Expression of glucose transporter-1 in cervical cancer and its precursors." Gynecologic Oncology, vol. 86, No. 2, Aug. 2002, pp. 138-143, XP002254294 Aug. 2002, ISSN: 0090-8258 cited in the application, p. 140, col. 2, line 7-p. 141, col. 1, line 2; table 3, p. 142, col. 1, paragraph 1.
Mueckler Mike et al: "Identification of an amino acid residue that lies between the exofacial vestibule and exofacial substrate-binding site of the Glut1 sugar permeation pathway." Journal of Biological Chemistry, vol. 272, No. 48, Nov. 28, 1997, pp. 30141-30146, XP002254295, ISSN: 0021-9258 cited in the application, figure 1.
Palker et al (Journal of Virological Methods 18:243-255, 1987). *
Sakashita et al (European Journal of Cancer 37:204-209, 2001). *
Tallet B et al: "Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies." AIDS Research and Human Retroviruses. United States Mar. 1, 2001, vol. 17, No. 4, Mar. 1, 2001, pp. 337-348, XP002254296 ISSN: 0889-2229, p. 346, col. 2, last paragraph, abstract.
Vannucci et al (Glia 21:2-21, 1997). *
Wood et al (British Journal of Nutrition 89:3-9, 2003). *
Young et al (American Journal of Cardiology 83:25H-30H, 1999). *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150133363A1 (en) * 2003-05-02 2015-05-14 Centre National De La Recherche Scientifique (Cnrs) Glut-1 as a receptor for htlv envelopes and its uses
US9777044B2 (en) * 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
US20180002383A1 (en) * 2003-05-02 2018-01-04 Centre National De La Recherche Scientifique Glut-1 as a receptor for htlv envelopes and its uses
US10231831B2 (en) 2009-12-08 2019-03-19 Cardiovalve Ltd. Folding ring implant for heart valve

Also Published As

Publication number Publication date
JP5612239B2 (ja) 2014-10-22
ES2740827T3 (es) 2020-02-06
EP2610265A1 (fr) 2013-07-03
DK1648926T3 (da) 2013-10-14
JP2007535293A (ja) 2007-12-06
EP3168227B1 (fr) 2019-05-22
EP1648926A1 (fr) 2006-04-26
EP3168227A1 (fr) 2017-05-17
WO2004096841A1 (fr) 2004-11-11
EP1648926B1 (fr) 2013-07-03
US8945583B2 (en) 2015-02-03
US20100056448A1 (en) 2010-03-04
US20080268424A1 (en) 2008-10-30
WO2004096841A8 (fr) 2006-01-19
EP2610265B1 (fr) 2016-11-16

Similar Documents

Publication Publication Date Title
US8945583B2 (en) GLUT-1 as a receptor for HTLV envelopes and its uses
Manel et al. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV
Sandefur et al. The I domain is required for efficient plasma membrane binding of human immunodeficiency virus type 1 Pr55Gag
Bour et al. The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection
Blond et al. An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor
Maurice et al. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell–activating polypeptide
Hoshino Cellular factors involved in HTLV-1 entry and pathogenicit
Paul et al. Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpu-mediated ER degradation of CD4
Sharma et al. Efficient infection of a human T-cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector.
Coskun et al. Expression of glucose transporter 1 confers susceptibility to human T-cell leukemia virus envelope-mediated fusion
Le Blanc et al. Multiple functions for the basic amino acids of the human T-cell leukemia virus type 1 matrix protein in viral transmission
Miller et al. Intravirion generation of the C-terminal core domain of HIV-1 Nef by the HIV-1 protease is insufficient to enhance viral infectivity
US20050158712A1 (en) Methods for purifying viral particles for gene therapy
Jones et al. Induction of human T cell leukemia virus type I receptors on quiescent naive T lymphocytes by TGF-β
Andrawiss et al. Murine leukemia virus particle assembly quantitated by fluorescence microscopy: role of Gag-Gag interactions and membrane association
Lucas et al. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu
Masuda et al. Analysis of receptor usage by ecotropic murine retroviruses, using green fluorescent protein-tagged cationic amino acid transporters
Alfadhli et al. Capsid-specific nanobody effects on HIV-1 assembly and infectivity
Camaur et al. Human immunodeficiency virus matrix tyrosine phosphorylation: characterization of the kinase and its substrate requirements
Lüftenegger et al. Analysis and function of prototype foamy virus envelope N glycosylation
US7803555B2 (en) Methods and compositions for use in the treatment of filovirus mediated disease conditions
FR2897062A1 (fr) Domaine peptidique necessaire a l'interaction entre l'enveloppe d'un virus appartenant au groupe d'interference de herv-w et un recepteur asct
US6054281A (en) Binding assays
US20180002383A1 (en) Glut-1 as a receptor for htlv envelopes and its uses
Hübner et al. Inhibition of viral assembly in murine cells by HIV-1 matrix

Legal Events

Date Code Title Description
AS Assignment

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FRAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BATTINI, JEAN-LUC GEORGES LAURENT;MANEL, NICOLAS GABRIEL ALBERT;KIM, FELIX JINHYUN;AND OTHERS;REEL/FRAME:017150/0363;SIGNING DATES FROM 20051209 TO 20051212

Owner name: UNIVERSITE MONTPELLIER II, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BATTINI, JEAN-LUC GEORGES LAURENT;MANEL, NICOLAS GABRIEL ALBERT;KIM, FELIX JINHYUN;AND OTHERS;REEL/FRAME:017150/0363;SIGNING DATES FROM 20051209 TO 20051212

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: UNIVERSITE MONTPELLIER, FRANCE

Free format text: MERGER;ASSIGNOR:UNIVERSITE MONTPELLIER 2;REEL/FRAME:047517/0408

Effective date: 20150617

AS Assignment

Owner name: UNIVERSITE DE MONTPELLIER, FRANCE

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED AT REEL: 047517 FRAME: 0408. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:UNIVERSITE MONTPELLIER 2;REEL/FRAME:047734/0743

Effective date: 20150617

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12